{"DataElement":{"publicId":"14719364","version":"1","preferredName":"Chemotherapy Agent Name","preferredDefinition":"The coded response used to indicate the name of the drug/agent that is being used for chemotherapy treatment..","longName":"2783412v1.00:14718773v1.00","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"2783412","version":"1","preferredName":"Chemotherapy Agent","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"2404910v1.0:2514627v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2404910","version":"1","preferredName":"Chemotherapy","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0094ACAF-12DD-1BCA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-09-13","modifiedBy":"ONEDATA","dateModified":"2005-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2514627","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1BB1AAFE-FB3A-4FE3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-08-23","modifiedBy":"ONEDATA","dateModified":"2006-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56934111-ECA2-2121-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-10","endDate":null,"createdBy":"UMLLOADER_CATISSUE","dateCreated":"2008-09-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9/28/10 Released for use in caTissue Suite version 1.1 and/or 1.2 per owners direction.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"14718773","version":"1","preferredName":"Chemotherapy Agent Name","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases._Something distinguishable as an identifiable class based on common qualities._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The words or language units by which a thing is known._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The words or language units by which a thing is known._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The words or language units by which a thing is known.","longName":"14718773v1.00","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"3","valueDescription":"Paclitaxel","ValueMeaning":{"publicId":"2739551","version":"1","preferredName":"Paclitaxel","longName":"2739551","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0248-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA0849F-CBD9-0214-E063-731AD00A7975","beginDate":"2020-08-20","endDate":null,"createdBy":"NELSONA","dateCreated":"2024-01-23","modifiedBy":"ONEDATA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"2","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"5242658","version":"1","preferredName":"Gemcitabine","longName":"5242658","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-98BB-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA0849F-CBDA-0214-E063-731AD00A7975","beginDate":"2020-08-20","endDate":null,"createdBy":"NELSONA","dateCreated":"2024-01-23","modifiedBy":"ONEDATA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"1","valueDescription":"Docetaxel","ValueMeaning":{"publicId":"2576637","version":"1","preferredName":"Docetaxel","longName":"2576637","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA0849F-CBDB-0214-E063-731AD00A7975","beginDate":"2020-08-20","endDate":null,"createdBy":"NELSONA","dateCreated":"2024-01-23","modifiedBy":"ONEDATA","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"4","valueDescription":null,"ValueMeaning":{"publicId":"7651581","version":"1","preferredName":"Sacituzumab govitecan","longName":"7651581v1.00","preferredDefinition":"An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sacituzumab Govitecan","conceptCode":"C102783","definition":"An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1823ADF-D239-476E-E053-4EBD850A6959","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"FINCHAMB","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA1FDF8-29DF-5A7B-E063-731AD00AD049","beginDate":"2024-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2024-01-23","modifiedBy":"FINCHAMB","dateModified":"2024-01-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"14719363","version":"1","preferredName":"Chemotherapy Agent Name","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The words or language units by which a thing is known.","longName":"14719363v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA16B4B-E7D0-3E9B-E063-731AD00AEE98","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2024-01-23","modifiedBy":"FINCHAMB","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"0FA084A3-756A-0205-E063-731AD00AD1D3","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2024-01-23","modifiedBy":"FINCHAMB","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Chemotherapy Agent Name","url":null,"context":"SWOG"},{"name":"SWOG - 1","type":"Alternate Question Text","description":"What chemotherapy regimen will be received if randomized to Standard of Care (SOC) chemotherapy arm?","url":null,"context":"SWOG"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA1DE6E-C22E-558F-E063-731AD00A5CB0","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2024-01-23","modifiedBy":"FINCHAMB","dateModified":"2024-02-23","changeDescription":null,"administrativeNotes":"1/23/24 Created for SWOG. Previous CDE was retired and new PV's needed to be added. BF","unresolvedIssues":null,"deletedIndicator":"No"}}